ÃâÒßѧÊÔÌâ
mX<D]Z< k Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
wngxVhu8Ld 1. Fas(CD95)/FasL
Uqkh@-6- 2. common chain of cytokine receptor
%`` FIv15w 3 . TCR/CD3 complex
8x+K4B"oe 4. negaive selection of thymocytes
H#1/H@I# 5. artificial active immune
~>C!l k 6. anti-idiotypic
)>=`[$D1t 7. IgSF
^tpy8TQ 8. Integrin
SK-|O9Ki 9. chemokine
K7CiICe 10. B7/CD28
%.Mtn%:I* ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
{(t (}-:Z 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
,,@_r&f: 2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣
ysL8w"t 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£
[t ^|l? 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
XbHcd8N T E6n;_{Se/S 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
?lbX.+ µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
+[*UC" Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
\Ud2]^D= 1. B7/CD28
Va9vDb6 2. Th1 subset
:S,#*rPKBK 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
Q9rE_}Z 4. antibody affinity maturation
!N!M
NsyDz 5. AP-1
!WbQ`]uN/# 6. single chain variable fragment£¨ScFv£©
+ J_W }G 7. NK cell receptor
F*Qw% 8. Zinkernagel-Doherty phenomenon
TzPVO>s 9. Ig fold
K<N0%c~ 10. CD40/CD40L
%3FI>\3 ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
{\ .2h 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£
ib&
|271gG 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
9#_49euy|P 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
,(lD5iN Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
;M}bQ88 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
!n
!~Bw 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
Ot v{#bB$ 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£
))eR Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
aIkxN& £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
xXLKL6F(\ Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
c
bS8~Xmj 1.Co-stimulators (or co-stimulating molecules)
R|tjvp-[} 2.NK-kB
igz&7U8gg 3.Immunoglobulin superfamily
.o
fYFK 4.antigen-presenting cell (APC)
<$ '#@jW 5.death domain
[D/q% 6.CCR and CXCR
t$s)S> 7.Lectin (or mitogen)
tXfB.[U 8.Clusters of differentiation, CD)
8B\,*JGY2 9.B7 family
I8?egDkk 10.Cytotoxic T lymphocyte, CTL)
r\L:JTZ$ 11.IL-15 and IL-15 receptor (IL-15R)
23+>K 12.MHC restriction
48w3gye 13.Affinity-chromatography
M*@MkN*u& 14.Cyctosprin A, CsA
WqwD"WX+w 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
LgB}!OLQ ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
R:OoQ^c 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
? p\'S
w: 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£
;Q-sie(# 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌص㡣
hZ$* sf Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
US4X CJxB ÃâÒßѧרҵ£º
`/Z8mFs Y 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
w[loV Ïû»¯ÄÚ¿Æ£º
./.E=
,j 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
T,j
xIFrF ѪҺ²¡Ñ§×¨Òµ£º
e@@kTny( 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
gTiDV{Ip Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
}|Cw]GW (רҵ»ù´¡: ÃâÒßѧ)
A qE,zW Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
h]G}E9\l 1. ADCC(antibody dependent cell-mediated cytotoxicity)
R"K{@8b 2. »·æß¾úËØ(cyclosporin)
Zni8im,_j 3. KIR(killer cell inhibitory receptor)
4 YI
,: 4. HLDA(human leucocyte differentiation antigen)
XWk/S $-d 5. Interleukin 18(IL-18)
|+ @ 6. ÕûºÏËØ(integrin)
vP
pbm 7. Fas/FasL
SlsMMD 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
0jE,=<W0> 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
!0E$9Xon 10. Th1/Th2
Zb8i[1 P 11. »ùÒòÒßÃç(DNAÒßÃç)
<S TwylL 12. chemokines and chemokine receptor
?=f\oH$ 13. ÃâÒßÄÍÊÜ
]TqcV8Q~ 14. ¹²´Ì¼¤·Ö×Ó
9sJbz=o]r 15. ËÀÍö½á¹¹Óò(death domain)
G2rxr ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
)`
' 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
o]PSyVg 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
}evc]?1( £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
Ow+7o@$"/ £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
wf<uG|90 £¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
j@2
-^q:` £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
j^986 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
I3s'44 Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
I-&/]<5y ÎÊ´ðÌâ(ÿÌâ25·Ö)
RhX
2qsva- 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
li,kW`j+t 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
l&U3jeW-o 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£
[uZU p*.V 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£